Brdm2-an aberrant hypomorphic p63 allele

Cell Death and Differentiation

Volumn 17, Issue 1, 2010, Pages 184-186

  Talos, F ^a   Wolff, S ^b   Beyer, U ^b   Dobbelstein, M ^b   Moll, U M ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRDM2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ALLELE; DEVELOPMENTAL STAGE; EXON; GENOTYPE; LETTER; LYMPHOMA; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; WILD TYPE;

EID: 79951910304     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.158     Document Type: Letter

References (10)

1. Wolff S, Talos F, Palacios G, Beyer U, Dobbelstein M, Moll UM. Cell Death Differ 2009; 16: 1108-1117.
2. Mikkola ML, Constazo A, Thesleff I, Roop DR, Koster MI. Cell Death Differ 2009; 17: 180-183.
3. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. Nature 1999; 398: 708-713.
4. Holcomb VB, Kim TM, Dumitrache LC, Ma SM, Chen MJ, Hasty P. Genesis 2007; 45: 275-281.
5. Yang A et al. Nature 1999; 398: 714-718.
6. Wu L, Zhu H, Nie L, Maki CG. Oncogene 2004; 23: 4032-4036.
7. Aberdam D, Mantovani R. Cell Death Differ 2009; 16: 1073-1074.
8. Ou HD, Lohr F, Vogel V, Mantele W, Dotsch V. EMBO J 2007; 26: 3463-3473.
9. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Genes Dev 1999; 13: 2658-2669.
10. Keyes WM et al. Proc Natl Acad Sci USA 2006; 103: 8435-8440.